Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Kayne Anderson Rudnick Investment Management LLC

Kayne Anderson Rudnick Investment Management LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 28.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,657 shares of the biopharmaceutical company’s stock after acquiring an additional 1,263 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $5,946,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Sachetta LLC boosted its position in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares in the last quarter. Stephens Consulting LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $26,000. West Paces Advisors Inc. grew its stake in Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 23 shares during the period. Crewe Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth $28,000. Finally, Lynx Investment Advisory acquired a new position in Regeneron Pharmaceuticals during the second quarter worth $33,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $1,145.03 on Monday. The firm has a 50 day simple moving average of $1,131.75 and a 200-day simple moving average of $1,032.63. The stock has a market cap of $126.17 billion, a price-to-earnings ratio of 33.83, a price-to-earnings-growth ratio of 3.93 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter in the previous year, the business earned $8.79 earnings per share. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the transaction, the executive vice president now directly owns 12,931 shares of the company’s stock, valued at approximately $13,540,179.41. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Marion Mccourt sold 1,137 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the sale, the executive vice president now owns 12,931 shares in the company, valued at $13,540,179.41. The disclosure for this sale can be found here. Insiders have sold a total of 9,270 shares of company stock valued at $10,695,833 over the last quarter. 7.48% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Morgan Stanley dropped their target price on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Wells Fargo & Company lifted their price objective on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Argus raised their target price on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. Finally, Truist Financial reiterated a “buy” rating and set a $1,200.00 price target (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $1,111.30.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.